Inhibition of cancer stem cell like cells by a synthetic retinoid

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Chen, Junwei ^a   Cao, Xin ^b   An, Quanlin ^b   Zhang, Yao ^a   Li, Ke ^a   Yao, Wenting ^a   Shi, Fuchun ^b   Pan, Yanfang ^b   Jia, Qiong ^a   Zhou, Wenwen ^a   Yang, Fang ^a   Wei, Fuxiang ^a   Wang, Ning ^a,c   Yu, Biao ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; ANTIMITOTIC AGENT; CASPASE 3; CISAPRIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; MESSENGER RNA; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WYC 209; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, MOUSE; NICOTINIC ACID DERIVATIVE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; TAZAROTENE;

APOPTOSIS; CANCER; CELL; DRUG; ENZYME; ENZYME ACTIVITY; INHIBITION; PROTEIN; RNA; TOXICITY; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B16-F1 CELL LINE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CARDIOTOXICITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOCOMPETENCE; IN VIVO STUDY; LONG TERM CARE; LUNG CANCER CELL LINE; LUNG METASTASIS; MALE; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; TUMOR REPOPULATING CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY; SKIN TUMOR; SYNTHESIS; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; NICOTINIC ACIDS; RECEPTORS, RETINOIC ACID; RETINOIDS; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRETINOIN;

EID: 85045259047     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-03877-7     Document Type: Article

References (31)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
3. Visvader, J. E. & Lindeman, G. J. Cancer stem cells: current status and evolving complexities. Cell. Stem. Cell. 10, 717-728 (2012).
4. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
5. Liu, J. et al. Soft fibrin gels promote selection and growth of tumorigenic cells. Nat. Mater. 11, 734-741 (2012).
6. Tan, Y. et al. Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression. Nat. Commun. 5, 4619 (2014).
7. Chen, J. et al. Efficient extravasation of tumor-repopulating cells depends on cell deformability. Sci. Rep. 6, 19304 (2016).
8. Penniston, K. L. & Tanumihardjo, S. A. The acute and chronic toxic effects of vitamin A. Am. J. Clin. Nutr. 83, 191-201 (2006).
9. Tallman, M. S. et al. All-trans-retinoic acid in acute promyelocytic leukemia. New Engl. J. Med. 337, 1021-1028 (1997).
10. Shih, M. Y. S. et al. Retinol esterification by DGAT1 is essential for retinoid homeostasis in murine skin. J. Biol. Chem. 284, 4292-4299 (2009).
11. Nau, H. Embryotoxicity and teratogenicity of topical retinoic acid. Skin. Pharmacol. 6(Suppl 1), 35-44 (1993).
12. Tang, X. H. & Gudas, L. J. Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol. Mech. Dis. 6, 345-364 (2011).
13. Maire, A. L. et al. Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr. Top. Med. Chem. 12, 505-527 (2012).
14. Chandraratna, R. A. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity. US Patent #5,089,509 (1989).
15. Ohta, K. et al. Retinoidal pyrimidinecarboxylic acids, unexpected diaza substituent effects in retinobenzoic acids. Chem. Pharm. Bull. 48, 1504-1513 (2000).
16. Boehm, M. F. et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 38, 3146-3155 (1995).
17. Brunel, J. M. et al. Highly enantioselective oxidation of sulfides mediated by a chiral titanium complex. J. Org. Chem. 60, 8086-8088 (1995).
18. Vasudevan, J. & Chandraratna, R. Rational design of tazarotene. J. Am. Aacd. Dermatol. 50, 148 (2004).
19. Shistik, G., Prakash, A. V., Fenske, N. A. & Glass, L. F. Treatment of locally metastatic melanoma: a novel approach. J. Drugs Dermat. 6, 830-832 (2007).
20. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
21. Widschwendter, M. et al. Methylation and silencing of the retinoic acid receptor-beta 2 gene in breast cancer. J. Natl. Cancer I 92, 826-832 (2000).
22. Goodyer, P., Dehbi, M., Torban, E., Bruening, W. & Pelletier, J. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene 10, 1125-1129 (1995).
23. Devarajan, E. et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21, 8843-8851 (2002).
24. Enari, M., Talanian, R. V., Wong, W. W. & Nagata, S. Sequential activation of ICE like and CPP32 like proteases during FAS mediated apoptosis. Nature 380, 723-726 (1996).
25. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
26. Vermeulen, L., de Sousa e Melo, F., Richel, D. J. & Medema, J. P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 13, e83-e89 (2012).
27. Wei, S. et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat. Med. 21, 457-466 (2015).
28. Lehmann-Che, J., Bally, C. & de Thé, H. Therapy resistance in APL. N. Engl. J. Med. 371, 1171-1172 (2014).
29. de Thé, H. Differentiation therapy revisited. Nat. Rev. Cancer 18, 117-127 (2018).
30. Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477-482 (2016).
31. Kumar, B. V. S. et al. Process for the preparation of 4, 4-dimethyl-6-ethynylthiochroman. US Patent #6,963,002 (2004).